Answers are grounded in this paper and cite their sources.
Sarcomatoid differentiation is an aggressive histologic transformation of renal cell carcinoma (RCC) associated with poor prognosis. We retrospectively analyzed 1,013 patients with metastatic RCC from the Korean Renal Cancer Study Group database, comparing clinicopathologic features and survival by sarcomatoid differentiation status and constructing a cumulative risk model combining sarcomatoid differentiation with other adverse factors. Overall and cancer-specific survival were estimated using the Kaplan–Meier method, and independent prognostic factors were identified using Cox proportional hazards models. Sarcomatoid differentiation was present in 206 patients (20.3%) and was associated with higher Fuhrman grade, more advanced pathologic stage, and higher rates of tumor necrosis and renal vein invasion (all p < 0.01). Median overall survival was shorter with sarcomatoid differentiation than without (18.8 vs 33.5 months; p < 0.001), as was cancer-specific survival (18.1 vs 33.1 months; p < 0.001). Sarcomatoid differentiation independently predicted poorer overall survival (hazard ratio 1.36, 95% confidence interval 1.08–1.73) and cancer-specific survival (hazard ratio 1.39, 95% confidence interval 1.10–1.77). The cumulative risk model showed a stepwise decline in cancer-specific survival, from a median of 36.0 months with 0–1 adverse factors to 10.0 months with four or more. These findings support incorporating sarcomatoid differentiation into cumulative risk stratification for metastatic RCC.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.